Calcitonin receptor mRNA expression in the human prostate

Urology

Volumn 47, Issue 3, 1996, Pages 376-381

  Wu, Guan ^a   Burzon, Daniel T ^b   Di Sant'Agnese, P Anthony ^b   Schoen, Susan ^b   Deftos, Leonard J ^b   Gershagen, Sten ^b   Cockett, Abraham T K ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN RECEPTOR; MESSENGER RNA;

ARTICLE; AUTOCRINE EFFECT; DNA SEQUENCE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE; PROTEIN LOCALIZATION; RECEPTOR DENSITY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

EID: 0029986916     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80456-7     Document Type: Article

References (38)

1. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 70: 254-268, 1992.
2. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma: recent findings and new concepts. Cancer 75: 1850-1859, 1995.
3. Pearse AG: The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic, and pathologic implications of the concepts. J Histochem Cytochem 17: 303-313, 1969.
4. Davis NS, di Sant'Agnese PA, Ewing JF, and Mooney RA: The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. J Urol 142: 884-888, 1989.
5. Sjöberg HE, Arver S, and Bucht E: High concentration of immunoreactive calcitonin of prostatic origin in human semen. Acta Physiol Scand 110: 101-102, 1980.
6. Bucht E, Arver S, and Sjöberg HE: Immunoextracted calcitonin from human seminal plasma constitutes different forms. Acta Physiol Scand 126: 289-293, 1986.
7. di Sant'Agnese PA: Calcitoninlike immunoreactive and bombesinlike immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 110: 412-415, 1986.
8. Abrahamsson P-A, Wadström LB, Alumets J, Falkmer S, and Grimelius L: Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 181: 675-683, 1986.
9. di Sant'Agnese PA, de Mesy Jensen KL, and Ackroyd RK: Calcitonin, katacalcin, and calcitonin gene-related peptide in the human prostate. An immunocytochemical and immunoelectron microscopic study. Arch Pathol Lab Med 113: 790-796, 1989.
10. Copp DH, Cameron EC, Cheney BA, Davidson AGF, and Henze KG: Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70: 638-649, 1962.
11. Friedman J, and Raisz LG: Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science 150: 1465-1467, 1965.
12. Warshawsky H, Goltzman D, Rouleau MF, and Bergeron JJ: Direct in vivo demonstration by radioautography of specific binding sites for calcitonin in skeletal and renal tissues of the rat. J Cell Biol 85: 682-694, 1980.
13. Silva OL, Wisneski LA, Cyrus J, Snider RH, Moore CF, and Becker KL: Calcitonin in thyroidectomized patients. Am J Med Sci 275: 159-164, 1978.
14. Becker KL, Snider RH, Moore CF, Monaghan KG, and Silva OL: Calcitonin in extrathyroidal tissues of man. Acta Endocrinol 92: 746-751, 1979.
15. Gorn AH, Lin HY, Yamin M, Auron PE, Flannery MR, Tapp DR, Manning CA, Lodish HF, Krane SM, and Goldring SR: Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J Clin Invest 90: 1726-1735, 1992.
16. Shah GV, Noble MJ, Austenfeld M, Weigel J, Deftos LJ, and Mebust WK: Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells. Prostate 21: 87-97, 1992.
17. Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL, O'Hara PJ, Sheppard PO, Stroop SD, and Thompson DL: Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol 46: 246-255, 1994.
18. Frendo JL, Pichaud F, Mourroux RD, Bouizar Z, Segond N, Moukhtar MS, and Jullienne A: An isoform of the human calcitonin receptor is expressed in TT cells and in medullary carcinoma of the thyroid. FEBS Lett 342: 214-216, 1994.
19. 2+ transients. Endocrinology 134: 596-602, 1994.
20. Don RH, Cox PT, Wainwright BJ, Baker K, and Mattick JS: 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 19: 4008, 1991.
21. Iwamura M, di Sant'Agnese PA, Wu G, Benning CM, Cockett AT, and Gershagen S: Overexpression of human epidermal growth factor receptor and c-erbB-2 by neuroendocrine cells in normal prostatic tissue. Urology 43: 838-843, 1994.
22. Segre GV, and Goldring SR: Receptors for secretin, calcitonin, parathyroid hormone (PTH) PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4: 309-314, 1993.
23. Nussenzveig DR, Mathew S, and Gershengorn MC: Alternative splicing of a 48-nucleotide exon generates two isoforms of the human calcitonin receptor. Endocrinology 136: 2047-2051, 1995.
24. Goldring SR, Gorn AH, Yamin M, Krane SM, and Wang JT: Characterization of the structural and functional properties of cloned calcitonin receptor cDNAs. Horm Metab Res 25: 477-480, 1993.
25. Nussenzveig DR, Thaw CN, and Gershengorn MC: Inhibition of inositol phosphate second messenger formation by intracellular loop one of a human calcitonin receptor. Expression and mutational analysis of synthetic receptor genes. J Biol Chem 269: 28123-28129, 1994.
26. Bonkhoff H, Stein U, and Remberger K: Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423: 291-294, 1993.
27. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, and van der Kwast TH: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100: 393-398, 1993.
28. Iwamura M, Gershagen S, Wu G, Cockett AT, di Sant'Agnese PA, and Abrahamsson P-A: Distribution and androgen receptor status of neuroendocrine cells in the prostate. J Urol 151: 296A, 1994.
29. Aprikian AG, Cordon-Cardo C, Fair WR, and Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71: 3952-3965, 1993.
30. Barsony J, and Marx SJ: Dual effects of calcitonin and calcitonin gene-related peptide on intracellular cyclic 3′,5′-monophosphate in a human breast cancer cell line. Endocrinology 122: 1218-1223, 1988.
31. Chakraborty M, Chatterjee D, Kellokumpu S, Rasmussen H, and Baron R: Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. Science 251: 1078-1082, 1991.
32. Su Y, Chakraborty M, Nathanson MH, and Baron R: Differential effects of the 3′,5′-cyclic adenosine monophosphate and protein kinase C pathways on the response of isolated rat osteoclasts to calcitonin. Endocrinology 131: 1497-1502, 1992.
33. Iwasaki Y, Iwasaki J, and Freake HC: Growth inhibition of human breast cancer cells induced by calcitonin. Biochem Biophys Res Commun 110: 235-242, 1983.
34. Ng KW, Livesey SA, Larkins RG, and Martin TJ: Calcitonin effects on growth and on selective activation of type II isoenzyme of cyclic adenosine 3′,5′-monophosphatase-dependent protein kinase in T 47D human breast cancer cells. Cancer Res 43: 794-800, 1983.
35. Nakamura A, Yamatani T, Arima N, Yamashita Y, Fujita T, and Chiba T: Calcitonin inhibits the growth of human gastric carcinoma cell line KATO III. Regul Pept 37: 183-194, 1992.
36. Kinoshita Y, Fukase M, Takenaka M, Nakada M, Miyauchi A, and Fujita T: Calcitonin stimulation of cyclic adenosine 3′,5′-monophosphate production with growth inhibition in human renal adenocarcinoma cell lines. Cancer Res 45: 4890-4894, 1985.
37. Bepler G, Rotsch M, Jaques G, Haeder M, Heymanns J, Hartogh G, Kiefer P, and Havemann K: Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects. J Cancer Res Clin Oncol 114: 235-244, 1988.
38. Deftos LJ, Hogu-Angeletti R, Chalberg C, and Tu S: PTHrP secretion is stimulated by CT and inhibited by CgA peptides. Endocrinology 125: 563-565, 1989.